INTRODUCTION

Top Abstract Introduction Materials and methods Results Discussion References

N-myc is a member of a small family of highly related genes encoding transcription factors critical for normal cell growth and differentiation (1, 33, 54, 60). Myc proteins form heterodimers with Max to function as transcriptional activators (2, 9, 10). Myc can also act as a transcriptional repressor (22, 38, 40, 57, 59). Individual myc family members have been independently conserved during vertebrate evolution, implying that they perform distinct functions. Several direct targets of c-Myc-Max have been identified (21, 24, 27), and N-Myc has been shown to increase the expression of a subset of these genes (41). c-myc is ubiquitously expressed, and its levels correlate with increased cell proliferation; N-myc, in contrast, is expressed only in the epithelial component of fetal tissues and transiently in pre-B lymphocytes (26, 31, 47, 62, 73).

The regulation of c-myc gene expression has been extensively studied. Its expression is controlled at multiple levels, including transcription initiation, transcription attenuation, and mRNA and protein degradation (6, 8, 11, 28, 34, 43, 63). Both the increase in transcription initiation and the loss of normal attenuation mechanisms contribute to the c-myc overexpression that occurs in human Burkitt's lymphoma (6, 37, 63).

Precisely regulated N-myc expression is critical for normal growth and differentiation, yet the specific mechanisms controlling normal N-myc expression have not been elucidated in detail (16, 64). Given their contrasting developmental expression patterns and tissue distributions, it is likely that distinct mechanisms operate to control c-myc and N-myc expression. Deregulated N-myc expression is strongly implicated in the pathogenesis of several important human malignancies, including small-cell lung cancer (48), Wilms' tumor (49), retinoblastoma (39), and neuroblastoma (5, 12, 61). Inappropriate overexpression of N-myc in these tumors is most often due to gene amplification, with a commensurate increase in mRNA and protein levels (5, 12, 33). N-myc gene amplification remains the single most important negative prognostic feature in the childhood tumor neuroblastoma, strongly supporting a role for deregulated N-myc expression in the pathogenesis of this malignancy (12, 56).

A limited number of studies to date have investigated the regulation of the human N-myc gene. A possible negative regulatory role for N-myc exon 1 and intron 1 sequences in the modulation of N-myc expression was first inferred from studies of c-myc regulation. Specific sequences within human c-myc exon 1 mediate transcriptional attenuation, and loss of these regions results in deregulated expression (6, 63). The presence of candidate regulatory sequences in exon 1 and/or intron 1 of N-myc is supported by the work of Xu and colleagues (71, 72), who noted that deletion of the exon 1/intron 1 region of the murine N-myc gene led to increased oncogenicity of transfected minigenes.

In previous work to define functional domains of the human N-myc promoter, we and others noted that N-myc sequences 5' to exon 1 were active in all cells examined, while inclusion of the 3' portion of exon 1 and a region within the first intron restored a physiologic N-myc expression pattern to promoter-reporter minigenes containing these constructs (30, 59, 68, 69). Constructs containing 3' exon 1 and 5' intron 1 were expressed only in cell types where endogenous N-myc transcripts accumulate, suggesting the presence of a tissue-specific regulatory element in this region.

In this study, we extended our findings by localizing more precisely the region within N-myc intron 1 that is responsible for directing expression to certain cell types. We have investigated the mechanism(s) by which this region controls N-myc expression in both neuroblastoma and N-myc-nonexpressing cells. Using nuclear run-on analyses, we have determined that the N-myc gene is actively transcribed even in those cell types that do not accumulate detectable amounts of N-myc transcript under steady-state conditions. Using deletional analysis of N-myc intron 1 in a promoter-reporter assay, we have identified a 116-bp region that directs tissue-specific expression. This N-myc tissue-specific element (TSE) can exert its effect in either orientation on transcripts initiated from the heterologous simian virus 40 (SV40) promoter when it is included within the transcribed sequence. This element bears no significant homology with known regulatory sequences and is located within an intron. Our data suggest that the N-myc intron TSE functions posttranscriptionally to regulate N-myc expression. The TSE therefore represents a novel mechanism contributing to the control of gene expression.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and methods Results Discussion References

Generation of N-myc promoter-reporter constructs. N-myc promoter-chloramphenicol acetyltransferase (CAT) reporter constructs were generated as previously described (59). pE/B N-myc CAT, which includes 2,023 bp of the N-myc promoter extending from 1872 to a BamHI site in exon 1 (+151), was generated by ligation of the EcoRI-BamHI 5' N-myc promoter fragment adjacent to CAT in pBluescript SK⁺ (Stratagene) (gift of Richard Wetzel, Washington University School of Medicine, St. Louis, Mo.). pE/E N-myc CAT includes an additional 907 bp of 3' N-myc sequence including all of exon 1 and a portion of intron 1 (872 to +1058).

Cell culture and transfection conditions. Human cell lines HL-60 (ATCC CCL 240), U937 (ATCC CRL 1593), and K-562 (ATCC CCL 243) were maintained in RPMI 1640 (Gibco, Grand Island, N.Y.) supplemented with 10% fetal calf serum (HyClone, Logan, Utah), 1 mM L-glutamine (Gibco), and 100 IU of penicillin-streptomycin per ml. Neuroblastoma lines SK-N-SH (single-copy N-myc; ATCC HTB 11), IMR-32 (amplified N-myc [25 copies]; ATCC CCL 127), NLF (30 copies), LHN (single copy), NLF (30 copies), NBL-S (single copy), and NMB (120 copies) (kind gifts of Garrett Brodeur, Children's Hospital of Philadelphia) and HeLa (ATCC CCL 2), A293 (ATCC CRL 1573), Caco2 (ATCC HTB 37), and A431 (ATCC CRL 1555) lines were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum (HyClone) and 1 mM L-glutamine (Gibco). Cells were maintained in a humidified 5% CO₂ atmosphere.

Assays of -Gal and CAT enzyme activity. Cells were harvested 48 h after transfection, and cell extracts were prepared by using reporter lysis buffer (Promega) according to the manufacturer's recommendations. Extracts were assayed immediately or stored for up to 1 week at 80°C. -Galactosidase (-Gal) assays were performed in microtiter plates, using GalactoLight Plus reagent (Tropix, Bedford, Mass.). Assays of CAT activity were performed by phase extraction, using minor modifications of published techniques (55) and as previously described (59). Relative CAT activity of each sample was normalized to its -Gal activity to control for variable transfection efficiencies among samples.

Northern and reverse transcriptase (RT)-mediated PCR (RT-PCR) analyses. RNA was harvested from cells or isolated nuclei using Trizol (Gibco). Northern blot analysis of N-myc expression in cultured cell lines was carried out according to standard techniques (53), using 20 µg RNA per lane for all cell lines except the neuroblastoma line NMB. Two micrograms of RNA was used for N-myc-amplified NMB, which contains 120 copies of the N-myc gene. A 506-bp XhoI-BamHI N-myc exon 2 fragment, labeled by the random hexamer method (PrimeIt; Stratagene), was used as a probe to detect N-myc transcripts.

Nuclear run-on assays. Nuclear run-on assays were performed with minor modifications of published techniques (13, 23). Nuclei were harvested from 10⁸ logarithmically growing cells by hypotonic lysis in 10 mM Tris (pH 7.4)-10 mM NaCl-3 mM MgCl₂-0.25% Nonidet P-40. Nuclei were washed once in lysis buffer, resuspended in 100 µl of glycerol storage buffer (40% glycerol, 50 mM Tris [pH 7.6], 5 M MgCl₂, 0.1 mM EDTA), and used immediately or stored at 80°C or in liquid nitrogen. Nascent transcripts were labeled in a reaction with 0.25 mM rATP, rCTP, and rGTP in 5 mM Tris (pH 8.0)-2.5 mM MgCl₂-25 mM KCl-2.5 mM dithiothreitol-200 µCi of [-³²P]UTP (3,000 Ci/mmol; NEN) for 30 min at 37°C. One unit of RNase-free DNase I (Worthington) or 500 U of RNase-free DNase I (Gibco-BRL) was added per reaction, and the mixtures were incubated at 37°C for 10 min. Reactions were stopped by the addition of 10× stop buffer (10% Sarkosyl or 2.5% sodium dodecyl sulfate [SDS], 1 mg of proteinase K per ml, 100 mM EDTA, 100 mM Tris [pH 7.6]) and additional incubation at 42°C for 30 min. RNA was purified either by extraction with 3 equal volumes of phenol-chloroform-isoamyl alcohol (25:24:1) and precipitation with 0.3 M sodium acetate and 100% ethanol using yeast tRNA as the carrier, or by purification through 3-ml Sephadex G-50 columns.

	RESULTS

Top Abstract Introduction Materials and methods Results Discussion References

Sequences within N-myc exon 1 and/or intron 1 direct its tissue-specific expression. In the course of initial studies to characterize the human N-myc promoter, we and others (30, 59, 68, 69) noted that the 5' portion of the promoter was active in all cell types examined, whereas constructs extending through all of exon 1 and a portion of intron 1 were active only in those cell types which express endogenous N-myc. Our original observation was reported for six neuroblastoma cell lines and two N-myc-nonexpressing cell lines (59). We have repeated these experiments and extended our N-myc promoter-reporter studies to two additional cell lines, U937 and A293, both of which do not accumulate significant amounts of N-myc RNA. We have confirmed that constructs containing the 3' region of exon 1 and a portion of intron 1 are inactive in nonexpressing cell lines (Table 1). No significant difference in reporter activity was noted between neuroblastoma lines transfected with the 5' promoter and those transfected with the construct containing the 3' exon 1/5' intron 1 region, implying that one or more sequence elements within this region function to modulate tissue-specific expression.

Human cell lines derived from multiple tissue lineages do not accumulate N-myc transcripts. We wished to study the regulation of both the endogenous N-myc gene and a series of transfected N-myc promoter-reporter constructs in cell lines that have been previously reported to lack detectable levels of N-myc transcript. To verify the absence of N-myc mRNA in these lines, we screened an extended panel of human cell lines derived from diverse tissue lineages for N-myc expression by Northern and RT-PCR analyses. As shown in Fig. 1a, the neuroblastoma line NMB, in which the N-myc gene is amplified (120 copies), shows elevated N-myc transcript levels. In addition, the single-copy neuroblastoma line NBL-S, which has an increased N-Myc protein half-life (18), also demonstrates elevated levels of N-myc mRNA. In contrast, of many cell lines, including some derived from epithelial tissue, only the colon carcinoma line Caco2 expresses detectable N-myc transcripts. Using the more sensitive RT-PCR technique with primers derived from sequences in exons 1 and 2 of the N-myc gene, we detected N-myc transcripts only in the neuroblastoma cell lines; a faint product was also visualized in K562 cells (Fig. 1b). On the basis of these findings, we chose several of these N-myc-nonexpressing cell lines for further studies of N-myc gene regulation.

View larger version (55K): [in this window] [in a new window]   FIG. 1.   Human cell lines derived from multiple lineages do not accumulate significant amounts of N-myc mRNA under steady-state conditions. (A) RNA was extracted from logarithmically growing cells, subjected to Northern electrophoresis using standard techniques, and probed with an N-myc exon 2-specific probe. One-tenth of the standard amount of total RNA, or 2 µg, was loaded for NMB, the N-myc-amplified line. Numbers in parentheses indicate N-myc copy numbers. (B) RNA from several N-myc-nonexpressing lines was subjected to RT-PCR using N-myc- and actin-specific primer pairs. Actin-specific primers were used to control for RNA integrity. Sizes are indicated in base pairs.

N-myc RNA levels in nonexpressing cell types are regulated posttranscriptionally. To determine whether the N-myc gene is transcriptionally silent in these nonexpressing cell lines, we performed nuclear run-on analyses. Double-stranded targets spanning the N-myc locus were used initially to detect nascent transcripts. Figure 2 shows results of nuclear run-on assays in the neuroblastoma lines IMR-32 and NBL-S, the colon carcinoma line Caco2, which demonstrates a low level of N-myc mRNA, and the N-myc-nonexpressing lines HeLa and HL-60. As expected, the N-myc gene is actively transcribed in both amplified and single-copy neuroblastoma lines as well as in Caco2. Interestingly, both HeLa and HL-60, which do not express detectable N-myc transcripts under steady-state conditions, also demonstrate active transcription of the gene, indicating that N-myc expression is controlled through a posttranscriptional mechanism. Transcription in IMR-32 is almost completely abrogated by treatment with 1 µM all-trans retinoic acid for 24 h as demonstrated by others, indicating specificity of the run-on probes for N-myc transcripts (66).

View larger version (34K): [in this window] [in a new window]   FIG. 2.   Transcription occurs across the entire N-myc gene in nonexpressing cell lines. The human N-myc locus is depicted at the top; locations of double-stranded targets used in nuclear run-on analyses are shown. Exons are boxed; nontranslated regions are shown in black. Autoradiographic signals from hybridization of targets with nascent RNAs from the single-copy neuroblastoma line NBL-S, the amplified line IMR-32 (25 copies of N-myc), and the nonexpressing lines HeLa, A293, Caco2, and HL-60 are shown. Signals were specific for human N-myc, as confirmed by the abrogation of N-myc transcription observed in IMR-32 cells treated with 1 µM all-trans retinoic acid (RA) for 24 h prior to harvest of nuclei. pBluescript (cloning vector) and human -actin were included as negative and positive controls, respectively.

Transcription attenuation occurs in both neuroblastoma and N-myc nonexpressing cell lines. Transcription attenuation plays an essential role in the control of c-myc expression (7, 14, 63), and attenuation has been demonstrated to control expression of the murine N-myc gene during development (19, 46, 71). To rigorously investigate the role of transcription attenuation in the regulation of human N-myc expression, we hybridized radiolabeled nascent transcripts with a series of single-stranded RNA probes to avoid quantitation of N-cym transcripts derived from a gene located on the opposite DNA strand (3) (Fig. 3).

View larger version (30K): [in this window] [in a new window]   FIG. 3.   Transcriptional attenuation in N-myc exon 1 occurs in both neuroblastoma and N-myc-nonexpressing cell lines. Autoradiographic signals are shown from hybridization of nascent transcripts from IMR-32 (30 copies of N-myc), NLF (30 copies), SK-N-SH (1 copy), HL-60, and U937 cells. Actin and transcription from the antisense strand at the 3' region of N-myc served as positive [Actin (+)] and negative [AS ()] controls, respectively. Relative signal intensities from PhosphorImager quantitation of the data were normalized for the uridine content of each nascent transcript. Relative intensities of 3' exon 1 (3' E1) are shown normalized to that of 5' exon 1 (5' E1) in the nonexpressing lines U937 and HL-60 and in the neuroblastoma lines IMR-32 (25 copies of N-myc), NLF (30 copies), and SK-N-SH (1 copy) to give a estimate of the degree of transcriptional attenuation. Exon 2 (E2) signal intensity was normalized to actin signal to allow relative comparison of polymerase density in N-myc translated regions between cell lines.

Unprocessed N-myc transcripts are detected in nonexpressing cell lines. To corroborate the findings of our nuclear run-on experiments, we used RT-PCR of nuclear RNA with intron-specific primer pairs to investigate whether unprocessed N-myc transcripts are detectable in HeLa cells, where stable N-myc message cannot be detected by Northern or RT-PCR analysis of total RNA. We extracted RNA from nuclei isolated identically as for nuclear run-ons and subjected it to RT-PCR using N-myc intron-specific primers. As predicted from nuclear run-on experiments, Fig. 4 demonstrates that unprocessed transcripts are found in the nonexpressing line HeLa in a qualitatively lower amount than in either the amplified neuroblastoma line NLF (30 copies of N-myc) or the single-copy line LHN. These results support the results of our nuclear run-on analyses in showing that the N-myc gene is actively transcribed in all cell lines examined, but unprocessed N-myc RNA is apparently rapidly degraded in cell types that do not accumulate significant amounts of N-myc mRNA.

View larger version (39K): [in this window] [in a new window]   FIG. 4.   Unprocessed N-myc transcripts are detected in cells that do not accumulate N-myc mRNA under steady-state conditions. Nuclear RNA was extracted and subjected to RT-PCR using the N-myc intron-specific primer pairs diagrammed at the top. An RT-specific product was observed in both NLF (30 copies of N-myc) and LHN (1 copy of N-myc) neuroblastoma cell lines and was also detected in the nonexpressing line HeLa (top). Actin primers were used to control for RNA integrity (middle). The N-myc product is not due to DNA contamination since no product was observed when RT was deleted during cDNA synthesis (bottom). The negative PCR control was a PCR reaction without added cDNA template. The diagram shows the locations of PCR primers (arrows).

Tissue-specific N-myc expression is mediated by a 116-bp element within intron 1. We sought to localize more precisely the domain within 3' exon 1/5' intron 1 that directs tissue-specific expression. To accomplish this, we generated a series of N-myc promoter-CAT reporter constructs bearing 3' nested deletions, using the construct pE/E N-myc CAT (Fig. 5), by limited exonuclease digestion. These were transfected into N-myc-expressing neuroblastoma lines and two N-myc-nonexpressing lines. As illustrated in Fig. 5, restriction of promoter activity to N-myc-expressing cells requires the inclusion of a 116-bp segment located between nt 598 and 714 within N-myc intron 1. Deletion of this element has no effect on the level of N-myc promoter activity in neuroblastoma cells, suggesting that a negative regulatory activity, rather than that of an enhancer element, is involved.

View larger version (35K): [in this window] [in a new window]   FIG. 5.   A region between nts 598 and 714 within N-myc intron 1 directs tissue-specific expression. A schematic diagram of human N-myc exon 1 is shown above a graphical representation of the promoter activity of 3' intron deletion constructs in SK-N-SH, HeLa, and HL-60 cells. The 3' end of each deletion construct is identified relative to the position of the major cap site. Promoter activity of each construct is expressed as CAT activity relative to that of the 5' N-myc promoter construct pE/B N-myc CAT, normalized to the -Gal activity of each sample, and is the mean ± standard error of the mean of at least three independent transfections.

Expression of N-myc promoter-CAT constructs are regulated by similar mechanisms that control expression of the endogenous N-myc gene. We next asked whether N-myc promoter-CAT reporter constructs, like the endogenous N-myc gene, were subject to posttranscriptional regulation in nonexpressing cell types. We transfected both neuroblastoma and N-myc-nonexpressing cell lines with the two reporter plasmids containing intron regions that flank the TSE and analyzed plasmid transcript expression by RT-PCR in parallel with CAT reporter assays. As shown in Fig. 6, NGP (150 copies of N-myc) neuroblastoma cells express transcripts from both constructs. Consistent with the reporter data shown in Fig. 5 is the finding that neither transfected HL-60 nor transfected HeLa cells contain detectable transcript from the +714 construct, which contains the 116-bp TSE. This element appears sufficient to extinguish reporter expression in nonexpressing cells, and reporter constructs containing the TSE do not generate stable transcripts in the same cells that do not accumulate detectable N-myc transcript. This finding implies that the transfected N-myc promoter-CAT reporter constructs are subject to regulation of expression that parallels that of the endogenous N-myc gene.

View larger version (66K): [in this window] [in a new window]   FIG. 6.   No transcripts are detected from N-myc promoter-CAT reporter constructs containing the N-myc TSE in N-myc-nonexpressing cell lines. The relevant N-myc promoter-CAT reporter constructs are diagrammed at the top (see Fig. 5 also). The two constructs both contain N-myc exon 1 (grey boxes) and extend 1,872 bp 5' to the major cap site. They differ from one another by the inclusion of the 116-bp TSE region. RNA was harvested from transiently transfected cells in parallel with preparation for CAT reporter assays, and expression of plasmid-specific transcripts was determined by RT-PCR. RT-PCR for actin transcripts was used as a control for RNA integrity. Arrows show the locations of PCR primers.

The N-myc intron element can function to abrogate expression from a heterologous promoter. We also questioned whether the N-myc TSE could function independently and whether it would be sufficient to silence transcript expression in the context of the heterologous SV40 promoter. To address this issue, we used a PCR-based approach to clone the 116-bp TSE adjacent to the promiscuous 5' N-myc promoter region in pE/B N-myc CAT, as well as into the pCAT3 (SV40 promoter) vector, within the transcribed region of the construct. We also cloned the TSE 5' to the transcriptional unit in the pCAT3 vector. Based on the results of nuclear run-on experiments showing active transcription of N-myc in all cell types examined, we predicted that the intron element would not silence reporter expression unless it was incorporated into the transcript.

View larger version (26K): [in this window] [in a new window]   FIG. 7.   The N-myc TSE can function independently to silence expression from a heterologous promoter. The N-myc TSE was cloned into pE/B N-myc CAT under the influence of the N-myc promoter or into pSV40 CAT3 to generate the promoter constructs diagrammed at the left. Constructs were transiently transfected into the N-myc-nonexpressing line HeLa and the neuroblastoma line NLF (30 copies of N-myc). Promoter activity is expressed as CAT activity relative to that of the relevant parent construct and normalized to the -Gal activity of each sample. Each bar represents the mean ± standard error of the mean of three independent transfections.

	DISCUSSION

Top Abstract Introduction Materials and methods Results Discussion References

In this study we investigated the mechanism by which human N-myc expression is restricted to particular cell types. We have determined that a major component of this regulation occurs posttranscriptionally. N-myc transcripts are synthesized in all cell types examined but are rapidly degraded in some prior to completion of their processing. We have found within the first intron of the human N-myc gene a 116-bp sequence, the TSE, that appears to be necessary and sufficient for destabilization of the nascent transcripts into which it is incorporated. Our results show excellent concordance between the regulation of the endogenous gene and promoter-reporter minigenes with respect to the measurable effects of the TSE.

Other published studies have suggested that sequences in human N-myc exon 1 and/or intron 1 play a critical regulatory role. Xu and colleagues (71, 72) first observed that a candidate regulatory element(s) within exon 1 and/or intron 1 of the murine N-myc gene appeared responsible for directing its expression to a limited subset of cell types and for decreasing its oncogenicity in ras cotransformation assays. Sequences within exon 1 of the human c-myc gene mediate transcription attenuation, and loss of these domains contributes to the deregulated c-myc expression characteristic of Burkitt's lymphoma (7, 42, 63). We and others have previously determined that sequences within the 3' portion of human N-myc exon 1 and/or the 5' portion of intron 1 appear to serve a regulatory function, based on their influence on linked reporter activity in a variety of murine and human cell lines (30, 59, 67).

The results presented here extend our previous findings and further emphasize the complexity of human N-myc regulation. Using a deletional analysis similar to ours, Woodruff and colleagues identified a 533-bp candidate regulatory region within human N-myc intron 1 and noted that this region contains a consensus sequence for the chicken lysozyme gene transcriptional silencer (69). The 116-bp N-myc intron TSE identified in our work lies within this larger region. We have observed active N-myc transcription even in cell types that do not accumulate N-myc mRNA, indicating that the TSE does not function as a transcriptional silencer. The reasons for discordance between our results and those reported by Woodruff and colleagues (69) attributing transcriptional silencer activity to this region of the human N-myc gene are not immediately clear. Our results regarding the activities of both the endogenous N-myc gene and transfected promoter-reporter minigenes are fully internally consistent, and we have extended our studies to multiple cell lines to avoid potential artifacts. In agreement with our results, Babiss and Friedman also observed posttranscriptional control of N-myc expression in cell lines where N-myc RNA does not accumulate (4). Another candidate regulatory element in N-myc intron 1 was recently identified based on sequence homology to the consensus binding site for nuclear retinoid receptors (20). This element lies just 5' to the TSE, and the relative contribution of this region to N-myc expression remains to be investigated.

Based on analysis of N-myc intron 1 deletion constructs in a functional reporter assay, we defined a second negative regulatory region, between nts 151 and 274 relative to the major cap site, that appears to function as a transcriptional attenuation site. In our functional assays, the inclusion of this site was associated with a 40 to 50% decrease in promoter activity in nonexpressing lines compared to activity observed in the neuroblastoma line, SK-N-SH. The results of nuclear run-on analyses using single-stranded targets demonstrated a significant decrease in RNA polymerase density in 3' exon 1 relative to 5' exon 1 as defined by the BamHI site at nt 151. Attenuation was seen in all cell lines but to a greater extent in nonexpressing lines. This site of attenuation detected by run-on analysis correlated qualitatively with the partial decrease in promoter activity measured in promoter deletion experiments. This region maps to a site of transcription attenuation previously noted in the murine N-myc gene (70, 72). Attenuation cannot account, however, for the total absence of N-myc transcript in nonexpressing cells, since similar polymerase densities are observed across translated exons 2 and 3 in both nonexpressing HeLa and HL-60 cells and neuroblastoma lines. The equal processivity of RNA polymerase II across translated exons 3' to the TSE also indicates that the TSE does not function through transcription attenuation.

The TSE of the human N-myc gene is unique in its ability to function posttranscriptionally from its location within an intron. RNA instability determinants, including those characterized in the human and murine c-myc genes, are often found in the 3' coding or untranslated regions (8, 11, 25, 28, 51). In the case of the human c-myc gene, each of the defined instability determinants can also destabilize a heterologous message, and the two appear to synergize to fully destabilize c-myc mRNA (8, 28). Similar instability elements have also been identified in the 3' untranslated region of the human N-myc gene. A member of the ELAV-like family recognizes two distinct AU-rich sequences in the 3' untranslated region of the human N-myc transcript, and its binding is associated with increased stability (15).

The data summarized above indicate that the TSE functions posttranscriptionally. This property is dependent on cell type, indicating the presence of a trans-acting factor, most likely a protein, that is differentially expressed. Based on the data presented here, we have considered four possible models for the effect of the TSE on RNA stability: (i) inhibition of normal splicing, (ii) activation of alternative splicing, (iii) regulation by antisense transcription, and (iv) direct regulation of pre-mRNA stability.

The tissue-specific gene regulation that we have observed does not appear to depend on the integrity of native splice acceptor and donor sites since many of our constructs lack such elements. This suggests that inhibition of normal splicing, possibly through inhibition of splicing enhancers with the generation of an aberrant transcript, does not account for the absence of N-myc mRNA in nonexpressing cell types (65). Alternative splicing could lead to the inclusion of a cryptic exon in the mature message that could similarly act to promote rapid degradation. The fact that the element operates in the antisense orientation (with inversion of any splice acceptor or donor sites) also argues against a model involving a specific effect of the TSE on splicing. In addition, to date we have not detected abnormally spliced N-myc products by PCR in nonexpressing cells (data not shown).

In a third model, antisense transcription from the N-cym gene could lead to the formation of RNA duplexes that could be targeted for degradation by cellular RNases (3). Although extensively documented in prokaryotes, gene regulation through endogenous antisense transcription has rarely been found in eukaryotes (reviewed in references 29, 50, and 58). Interestingly, Krystal et al. showed the presence of stable nonpolyadenylated antisense N-myc transcripts in small-cell lung cancer lines and also demonstrated RNA-RNA duplexes (35). However, a direct antisense mechanism would predict an inverse relationship between N-cym and N-myc expression. Previous work and preliminary experiments in our laboratory have shown that N-cym expression occurs in every cell line where N-myc transcripts have been detected (3, 35, 44). It is still possible that a differentially expressed trans-acting protein or RNase acts to (de)stabilize primary N-myc transcripts through RNA duplex recognition motifs.

Our data are also consistent with a model in which the TSE leads to rapid degradation of primary N-myc transcripts in selected cell types. The transcript may be targeted for rapid degradation by a trans-acting factor in N-myc-nonexpressing cells, or the naturally short-lived transcript could be stabilized in cells that are programmed to express N-myc. Whatever the mechanism, degradation in nonexpressing cells must be extremely efficient, since transcription and processing of the primary transcript, with removal of regulatory intron sequences, occur coordinately (32, 45).

The fact that the TSE functions when placed in the antisense orientation is puzzling, and current models must account for the observation. An antisense mechanism is consistent with this observation, and primary transcripts generated from transiently transfected reporter genes could complex with endogenous antisense transcripts, thus accounting for our results. The fourth model, a direct effect on pre-mRNA stability, is more difficult to reconcile with this observation. However, based on a model of a protein-RNA interaction that mediates rapid degradation of N-myc pre-mRNA, two predictions can be made: (i) the RNA sequence motif responsible for tissue-specific regulation is preserved in both the sense and antisense orientations; and (ii) the N-cym gene located on the opposite DNA strand is subject to the same type of regulation, since the TSE is contained within the first intron of the N-cym gene. Modeling of RNA structure does indicate possible conservation of a predicted stable loop in both orientations (data not shown). Previous work also demonstrates coordinate expression of both N-myc and N-cym RNAs, and our preliminary results with nuclear run-on analysis show that the N-cym gene, like the N-myc gene, is regulated posttranscriptionally in nonexpressing cells (3, 36, 44). Further investigation will clarify the mechanism of TSE mediated N-myc gene regulation.

We consistently saw greater expression from constructs containing a single TSE cloned in the antisense orientation in neuroblastoma cells but not when two antisense TSE units are contained within the transcribed region. We cannot account for this observation, but it could be related to relatively greater affinity of a protein for an RNA structure contained within the TSE imparted by flanking sequences unique to the antisense orientation. Such an increase in affinity could conceivably be disrupted by changes in secondary and/or tertiary structure that occur when two TSE units are juxtaposed.

In summary, our laboratory has identified an element within the first intron of N-myc, the TSE, that functions posttranscriptionally to regulate N-myc transcripts levels in selected cell types. The role that the TSE plays in regulating N-myc expression during normal development and how this regulation occurs is the subject of ongoing work.